Mink Therapeutics Inc
INKT
NASDAQ
Biotechnology
$11.27
USD
+0.27 (+2.45%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $54.80M
Volume 6.8K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-12.47M
TTM
-28.1%
YoY
Operating Cash Flow
$-6.32M
TTM
+24.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.3 | 1.8 | 1.8 | 1.8 | 1.7 |
Other Operating Expenses | 0.2 | 0.4 | 0.2 | -0.6 | 0.0 |
Total Operating Expenses | 2.7 | 4.1 | 3.2 | 2.7 | 2.9 |
Operating Income | -2.7 | -4.1 | -3.2 | -2.7 | -2.9 |
EBITDA | -2.6 | -4.0 | -3.1 | -2.7 | -2.8 |
Other Income / Expense | -0.1 | -0.2 | 0.2 | -0.0 | 0.1 |
Total Other Income / Expense | -0.1 | -0.2 | 0.3 | 0.1 | 0.1 |
Income Before Income Taxes | -2.8 | -4.2 | -2.9 | -2.6 | -2.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -2.8 | -4.2 | -2.9 | -2.6 | -2.7 |
Consolidated Net Income / Loss | -2.8 | -4.2 | -2.9 | -2.6 | -2.7 |
Net Income Attributable to Common Shareholders | -2.8 | -4.2 | -2.9 | -2.6 | -2.7 |
Basic EPS | -$0.70 | -$1.06 | -$0.65 | -$0.55 | -$0.57 |
Diluted EPS | -$0.70 | -$1.06 | -$0.65 | -$0.55 | -$0.57 |
Basic Shares Outstanding | 4.0M | 4.0M | 4.4M | 4.7M | 4.8M |
Diluted Shares Outstanding | 4.0M | 4.0M | 4.4M | 4.7M | 4.8M |